II. Indications
-
HIV Infection as part of combination therapy (not a first-line agent)
- Indicated for resistance to other Protease Inhibitors
III. Contraindications
- Sulfonamide Allergy (Exercise caution if used)
- Moderate to severe hepatic Impairment (Chil-Pugh Class B or C)
IV. Mechanism
V. Medications
VI. Dosing
-
General
- Use with Ritonavir, in addition to other Antiretrovirals as part of combination therapy
- Indicated as second line agent in HIV Treatment experienced patients with resistance to other Protease Inhibitors
- Adult
- Tipranavir 500 mg orally twice daily AND
- Ritonavir 200 mg orally twice daily
- Child (age >=2 years)
- Tipranavir 14 mg/kg (or 375 mg/m2) orally twice daily AND
- Ritonavir 6 mg/kg (or 150 mg/m2) orally twice daily
VII. Adverse Effects
- See Protease Inhibitor for adverse effects attributed to the class
- Hepatotoxicity
- Severe hepatitis (fatalities have occurred)
- Higher risk in Hepatitis B and Hepatitis CVirus coinfection
- Avoid in Moderate to severe hepatic Impairment (Chil-Pugh Class B or C)
-
Intracranial Hemorrhage (rare)
- Higher risk in CNS neoplasm, Closed Head Injury, Coagulopathy or Anticoagulants
VIII. Safety
- Avoid in Lactation
- Avoid in pregnancy
IX. Drug Interactions
- Multiple Drug Interactions
- See Protease Inhibitor
- Ritonavir, even at its lower boosting dose, has numerous Drug Interactions
- As with other Protease Inhibitors, check a formal Drug Interaction application before prescribing
-
CYP3A4 Substrates (e.g. Atorvastatin, Etravirine. other Protease Inhibitors)
- Avoid in combination with Tipranavir (risk of significant toxicity)
-
Oral Contraceptives (OCP)
- Decreased OCP effectiveness
- Use backup or alternative Contraception
-
Voriconazole
- Ritonavir decreases Voriconazole levels and efficacy
- Avoid concurrent use if possible
-
Tricyclic Antidepressants
- Monitor levels
-
Immunosuppressants
- Monitor levels
-
Clarithromycin
- Decrease Clarithromycin dose if Creatinine Clearance <60 ml/min
X. Resources
XI. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
- Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
aptivus (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
APTIVUS 250 MG CAPSULE | $15.98 each |